Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
85.70
-0.29 (-0.34%)
At close: Oct 13, 2025, 4:00 PM EDT
85.75
+0.05 (0.06%)
After-hours: Oct 13, 2025, 7:59 PM EDT
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$848,213
Profits / Employee
$218,747
Market Cap
214.06B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
Dec 31, 2018 | 69,000 | 0 | - |
Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
Dec 31, 2016 | 68,000 | 0 | - |
Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
AbbVie | 55,000 |
MRK News
- 17 hours ago - Merck: An Undervalued Stock In An Expensive Market - Seeking Alpha
- 3 days ago - Biotech Stocks Have Struggled Since 2021. Why They're Coming Back. - Barrons
- 3 days ago - High Margins, Lower Price: Is This Merck Stock's Buying Window? - Forbes
- 4 days ago - Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025 - Business Wire
- 4 days ago - Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025 - Business Wire
- 6 days ago - Merck Completes Acquisition of Verona Pharma - Business Wire
- 7 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 7 days ago - Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases - Business Wire